| Literature DB >> 35222584 |
Osama H Al-Jiffri1, Shehab M Abd El-Kader2.
Abstract
BACKGROUND: Chronic primary insomnia is a prevalent sleep disorder that is associated with adverse effects on health outcomes. Exercise is often considered a non-pharmacological approach that could have beneficial effects on sleep.Entities:
Keywords: Aerobic exercise; chronic primary insomnia; inflammatory cytokines; resistance exercise; sleep quality
Mesh:
Year: 2021 PMID: 35222584 PMCID: PMC8843261 DOI: 10.4314/ahs.v21i3.30
Source DB: PubMed Journal: Afr Health Sci ISSN: 1680-6905 Impact factor: 0.927
Figure (1)Subjects screening and recruitment CONSORT diagram
Baseline characteristics of study participants
| Characteristic | Group (A) | Group (B) | Significance |
| 43.64 ± 3.97 | 41.51 ± 4.26 | P>0.05 | |
| 18/12 | 20/10 | P>0.05 | |
| 34.19 ± 3.41 | 33.28 ± 3.92 | P>0.05 | |
|
| 0.89 ± 0.27 | 0.88 ± 0.25 | P>0.05 |
| 137.83 ± 8.14 | 135.92 ± 7.69 | P>0.05 | |
| 86.31 ± 5.16 | 84.72 ± 4.91 | P>0.05 | |
| 11.74 ± 1.68 | 12.25± 1.42 | P>0.05 | |
| 162.85 ± 13.12 | 164.76 ± 14.35 | P>0.05 |
BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; Hb: Hemoglobin; HRmax: Maximum heart rate.
Mean value and significance of sleep parameters and inflammatory markers of group (A) before and at the end of the study
| Mean + SD | t-value | Significance | ||
| Pre | Post | |||
| 34.19 ± 3.41 | 28.26 ± 3.12 | 7.95 | P<0.05 | |
| 320.67 ± 25.92 | 354.23 ± 28.51 | 11.46 | P <0.05 | |
| 67.85 ± 6.34 | 83.32 ± 7.19 | 10.13 | P <0.05 | |
| 12.37 ± 2.68 | 16.11 ± 2.75 | 7.26 | P <0.05 | |
| 78.91 ± 7.54 | 63.25 ± 6.82 | 9.67 | P <0.05 | |
| 90.13 ± 8.63 | 71.27 ± 6.94 | 10.21 | P <0.05 | |
| 6.17 ± 1.82 | 3.75 ± 1.41 | 6.83 | P <0.05 | |
| 2.76 ± 0.84 | 1.69 ± 0.73 | 5.72 | P <0.05 | |
| 5.91 ± 1.35 | 8.22 ± 1.64 | 6.43 | P <0.05 | |
BMI: Body mass index; REM: rapid eye movements; TNF-α: tumor necrosis factor – alpha; IL-6: Interleukin-6; IL-10: Interleukin-10
indicates a significant difference between the two groups, P < 0.05.
Mean value and significance of sleep parameters and inflammatory markers of group (B) before and at the end of the study
| Mean + SD | t-value | Significance | ||
| Pre | Post | |||
| 33.28 ± 3.72 | 33.75 ± 3.78 | 0.481 | P>0.05 | |
| 323.74 ± 27.19 | 319.24 ± 26.97 | 1.82 | P>0.05 | |
| 69.15 ± 5.84 | 68.21 ± 5.76 | 1.17 | P>0.05 | |
| 12.71 ± 2.53 | 12.15 ± 2.68 | 0.614 | P>0.05 | |
| 76.54 ± 6.91 | 78.13 ± 7.11 | 1.15 | P>0.05 | |
| 88.75 ± 8.42 | 89.66 ± 8.54 | 0.871 | P>0.05 | |
| 5.98 ± 1.75 | 6.11 ± 1.81 | 0.493 | P>0.05 | |
| 2.65 ± 0.71 | 2.94 ± 0.78 | 0.476 | P>0.05 | |
| 6.13 ± 1.47 | 5.86 ± 1.43 | 0.392 | P>0.05 | |
BMI: Body mass index; REM: rapid eye movements; TNF-α: tumor necrosis factor – alpha; IL-6: Interleukin-6; IL-10: Interleukin-10.
Mean value and significance of sleep parameters inflammatory markers in group (A) and group (B) at the end of the study
| Mean + SD | t-value | Significance | ||
| Group (A) | Group (B) | |||
| 28.26 ± 3.12 | 33.75 ± 3.78 | 6.19 | P<0.05 | |
| 354.23 ± 28.51 | 319.24 ± 26.97 | 9.24 | P <0.05 | |
| 83.32 ± 7.19 | 68.21 ± 5.76 | 8.23 | P <0.05 | |
| 16.11 ± 2.75 | 12.15 ± 2.68 | 6.35 | P <0.05 | |
| 63.25 ± 6.82 | 78.13 ± 7.11 | 7.56 | P <0.05 | |
| 71.27 ± 6.94 | 89.66 ± 8.54 | 8.48 | P <0.05 | |
| 3.75 ± 1.41 | 6.11 ± 1.81 | 5.27 | P<0.05 | |
| 1.69 ± 0.73 | 2.94 ± 0.78 | 4.75 | P<0.05 | |
| 8.22 ± 1.64 | 5.86 ± 1.43 | 5.18 | P<0.05 | |
BMI: Body mass index; REM: rapid eye movements; TNF-α: tumor necrosis factor – alpha; IL-6: Interleukin-6; IL-10: Interleukin-10
indicates a significant difference between the two groups, P < 0.05.